Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2, a routine system update with no user-facing changes to content or studies.SummaryDifference0.1%

- Check20 days agoChange DetectedMinor system update: Revision changed from v3.4.0 to v3.4.1 with no visible changes to study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThese changes are cosmetic UI and metadata updates that do not affect study content, enrollment, or results. Updates include showing the glossary toggle, capitalization fixes for QC-related fields, and the addition of 'No FEAR Act Data' with revision 'v3.4.0' replacing prior labels.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays 'Revision: v3.3.4' in the footer, replacing the previous 'Revision: v3.3.3'. No other content changes were made.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Georgia location to the Study Locations section and updated the page revision to v3.3.3; removed the Georgia Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.